NasdaqCM - Nasdaq Real Time Price USD

enVVeno Medical Corporation (NVNO)

3.6300
-0.1400
(-3.71%)
At close: May 8 at 4:00:01 PM EDT
3.8400
+0.21
+(5.79%)
After hours: May 8 at 7:59:39 PM EDT
Loading Chart for NVNO
  • Previous Close 3.7700
  • Open 3.8000
  • Bid 3.6000 x 100
  • Ask 3.7600 x 100
  • Day's Range 3.6100 - 3.8250
  • 52 Week Range 2.0280 - 6.4800
  • Volume 113,233
  • Avg. Volume 94,747
  • Market Cap (intraday) 63.656M
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1800
  • Earnings Date Jul 29, 2025 - Aug 4, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.50

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

www.envveno.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVNO

View More

Performance Overview: NVNO

Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NVNO
20.20%
S&P 500 (^GSPC)
3.70%

1-Year Return

NVNO
28.82%
S&P 500 (^GSPC)
9.18%

3-Year Return

NVNO
16.74%
S&P 500 (^GSPC)
37.36%

5-Year Return

NVNO
61.79%
S&P 500 (^GSPC)
93.32%

Compare To: NVNO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVNO

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    66.11M

  • Enterprise Value

    28.15M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.73

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.07%

  • Return on Equity (ttm)

    -52.88%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.33M

  • Diluted EPS (ttm)

    -1.1800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.94M

  • Total Debt/Equity (mrq)

    2.56%

  • Levered Free Cash Flow (ttm)

    -10.51M

Research Analysis: NVNO

View More

Company Insights: NVNO

Research Reports: NVNO

View More

People Also Watch